<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Hypermethylation of CpG islands in the promoter region of <z:hpo ids='HP_0011420'>death</z:hpo>-associated protein kinase (DAP-kinase) coupled with the loss of gamma-interferon-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> have been reported in B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> suggesting a role in pathogenesis or prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>Along with B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, pediatric <z:hpo ids='HP_0002665'>lymphomas</z:hpo> also include T-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin disease</z:e>, each with unique prognoses </plain></SENT>
<SENT sid="2" pm="."><plain>The purpose of this study was to elucidate epigenetic changes in the DAP-kinase promoter region of pediatric cases to determine associations with aberrant hypermethylation </plain></SENT>
<SENT sid="3" pm="."><plain>PROCEDURES: Thirty-nine cases of different lymphoid pathology [10 Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 1 B-cell NHL; 7 T-cell lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>; 4 anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (LCL); 2 B-cell LCL; 14 nodular sclerosing <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin disease</z:e> (NSHD); and 1 B-cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL)] had methylation-specific polymerase chain reaction performed on <z:chebi fb="0" ids="17137">bisulfite</z:chebi>-treated DNA, which distinguishes the methylation status of the promoter region, and DAP-kinase <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression assays performed on available specimens </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In <z:mpath ids='MPATH_458'>normal</z:mpath> lymphocytes, the CpG islands in the promoter region were unmethylated, as were the T-cell lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and anaplastic LCL </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, 100% of the Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (10/10) and B-cell ALL (1/1) were hypermethylated </plain></SENT>
<SENT sid="6" pm="."><plain>Of the specimens with <z:chebi fb="2" ids="33699">mRNA</z:chebi> available, 7/8 Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> had no DAP-kinase <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression compared to <z:mpath ids='MPATH_458'>normal</z:mpath> expression in 3/3 and 4/4 T-cell lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and NSHD, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: In these pediatric <z:mp ids='MP_0002022'>lymphoid tumors</z:mp>, hypermethylation of the DAP-kinase promoter region with associated loss of DAP-kinase gene expression was associated with B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and thus may be important in the development and/or provide a prognostic tool in B- cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>